Loading…
Pharmaceuticals - Active Pharmaceutical Ingredients Manufacturing · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 3.83% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Debt / 36-month avg market cap | 0% | < 33% | Pass |
| Cash + interest-bearing securities / 36-month avg market cap | 0% | < 33% | Pass |
| Accounts receivable / 36-month avg market cap | 1.6% | < 33% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free3.83% of any dividend from DIVISLAB should be given to charity. Calculate your amount →
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.
DIVISLAB has modestly positive three- and six-month performance, trades close to its 52-week high, and maintains a supportive moving-average structure despite a soft last month, indicating a mild uptrend. Sector-level sentiment is not specified.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.